Literature DB >> 18007144

Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays.

Franklin M Mullins1, Lisa Dietz, Marla Lay, James L Zehnder, James Ford, Nicolette Chun, Iris Schrijver.   

Abstract

PURPOSE: The CDH1 gene encodes the cell adhesion protein E-cadherin, and CDH1 germline mutations are associated with hereditary diffuse gastric cancer. Identification of individuals at high risk of developing diffuse gastric cancer affords the opportunity for endoscopic screening or elective prophylactic gastrectomy. We set out to develop a CDH1 sequencing assay for clinical use.
METHODS: All exons of the CDH1 gene were amplified and sequenced with published and modified primers.
RESULTS: While validating the assay, we encountered a case in which a single nucleotide polymorphism located in intron 15 led to allele dropout and therefore to a false-negative result. The polymorphism leading to allele dropout was located within a primer-binding sequence, five bases away from the 3' end of the primer. A frameshift mutation in exon 15 was detected by an alternative primer that binds away from the polymorphic site. A search of the University of California Santa Cruz single nucleotide polymorphism database revealed other polymorphisms located within primer-binding sites. A total of 12 primers in nine primer sets were modified to minimize allele dropout risk.
CONCLUSION: The approach of designing primers to avoid known single nucleotide polymorphisms can be generalized to the design of any polymerase chain reaction-based assay and should be employed whenever possible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18007144     DOI: 10.1097/gim.0b013e318159a369

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  11 in total

1.  Concordance between Research Sequencing and Clinical Pharmacogenetic Genotyping in the eMERGE-PGx Study.

Authors:  Laura J Rasmussen-Torvik; Berta Almoguera; Kimberly F Doheny; Robert R Freimuth; Adam S Gordon; Hakon Hakonarson; Jared B Hawkins; Ammar Husami; Lynn C Ivacic; Iftikhar J Kullo; Michael D Linderman; Teri A Manolio; Aniwaa Owusu Obeng; Renata Pellegrino; Cynthia A Prows; Marylyn D Ritchie; Maureen E Smith; Sarah C Stallings; Wendy A Wolf; Kejian Zhang; Stuart A Scott
Journal:  J Mol Diagn       Date:  2017-05-11       Impact factor: 5.568

2.  Multi-ethnic SULT1A1 copy number profiling with multiplex ligation-dependent probe amplification.

Authors:  Raymon Vijzelaar; Mariana R Botton; Lisette Stolk; Suparna Martis; Robert J Desnick; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2018-05-23       Impact factor: 2.533

3.  Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.

Authors:  Jonathan C Dudley; Grzegorz T Gurda; Li-Hui Tseng; Derek A Anderson; Guoli Chen; Janis M Taube; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

4.  The identification and management of hereditary diffuse gastric cancer in a large Jordanian family.

Authors:  Henry T Lynch; Ibrahim Aldoss; Jane F Lynch
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

5.  Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences.

Authors:  Kathy A Mangold; Vivien Wang; Scott M Weissman; Wendy S Rubinstein; Karen L Kaul
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

6.  Modification of primers for GRHPR genotyping: avoiding allele dropout by single nucleotide polymorphisms and homology sequence.

Authors:  Naohisa Takaoka; Tatsuya Takayama; Miki Miyazaki; Masao Nagata; Seiichiro Ozono
Journal:  Urol Res       Date:  2008-11-04

Review 7.  Hereditary diffuse gastric cancer: prophylactic surgical oncology implications.

Authors:  Henry T Lynch; Edibaldo Silva; Debrah Wirtzfeld; Pamela Hebbard; Jane Lynch; David G Huntsman
Journal:  Surg Clin North Am       Date:  2008-08       Impact factor: 2.741

8.  Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.

Authors:  Ming-Tseh Lin; Stacy L Mosier; Michele Thiess; Katie F Beierl; Marija Debeljak; Li-Hui Tseng; Guoli Chen; Srinivasan Yegnasubramanian; Hao Ho; Leslie Cope; Sarah J Wheelan; Christopher D Gocke; James R Eshleman
Journal:  Am J Clin Pathol       Date:  2014-06       Impact factor: 2.493

9.  Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing.

Authors:  Saeam Shin; Yoonjung Kim; Seoung Chul Oh; Nae Yu; Seung-Tae Lee; Jong Rak Choi; Kyung-A Lee
Journal:  Oncotarget       Date:  2017-05-23

10.  High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.

Authors:  Hongdo Do; Michael Krypuy; Paul L Mitchell; Stephen B Fox; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2008-05-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.